DAFTAR PUSTAKA

1. Nickel JC. The overlapping lower urinary tract symptoms of benign

prostatic hyperplasia and prostatitis. Curr Opin Urol 2006;16:5-10.

2. Neal DE, Neal RR, Donovan J. Benign Prostatic Hyperplasia. In: Health
Care Needs Assessment: The Epidemiologically Based Needs Assessment
Reviews. Edited by Stevens A, Raftery J, Mant J, Simpson S. Abington:
Radcliffe Publishing, chapt. 12, 2004: 91-158.

3. Konwar R, Chattopadhyay N, Bid HK. Genetic polymorphism and

pathogenesis of benign prostatic hyperplasia. BJU Int 2008 Aug
5;102:536-44

4. Rosenberg MT, Staskin DR, Kaplan SA, et al. A practical guide to the
evaluation and treatment of male lower urinary tract symptoms in the
primary care setting. Int J Clin Pract 2007;61:1535-46.

5. Edwards JL. Diagnosis and management of benign prostatic hyperplasia.

Am Fam Physician 2008;77:1403-10.

6. Canadian Prostate Cancer Network. International Prostate Symptom Score

(IPSS). http://www.cpcn.org/ipss.pdf. diakses 2 September 2015.

7. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal
examination and serum prostate specific antigen in the early detection of
prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol
1994;151:1283-90

8. Briganti A, Capitanio U, Suardi N. Benign Prostatic Hyperplasia and Its

Aetiologies. EUROPEAN UROLOGY SUPPLEMENT S 8 ( 2 00 9 ) 865
871.

9. Liu L, Li Q, Han P, et al. Evaluation of interleukin-8 in expressed prostatic

secretion as a reliable biomarker of inflammation in benign prostatic
hyperplasia. Urology 2009;74:3404.

10. Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, Walsh PC.
Prostate volume changes over time: results from the Baltimore
Longitudinal Study of Aging. J Urol 2009;182:145862
11. KyprianouN, TuH, Jacobs SC. Apoptotic versus proliferative activities in
human benign prostatic hyperplasia. Hum Pathol 1996;27: 66875.

12. Coffey DS, Walsh PC. Clinical and experimental studies of benign
prostatic hyperplasia. Urol Clin North Am 1990;17:46175.

13. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in

elderly men. Aging Male 2002;5:98102.

14. Hammarsten J, Hogstedt B, Holthuis N, MellstromD. Components of the

metabolic syndrome-risk factors for the development of benign prostatic
hyperplasia. Prostate Cancer Prostatic Dis 1998;1:15762

15. Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and

insulin profile of men with fast annual growth rates of benign prostatic
hyperplasia. Blood Press 1999;8:2936

16. Kramer G, Steiner GE, Handisurya A, et al. Increased expression of

lymphocyte-derived cytokines in benign hyperplastic prostate tissue,
identification of the producing cell types, and effect of differentially
expressed cytokines on stromal cell proliferation. Prostate 2002;52:4358.

17. Bierhoff E, Vogel J, Benz M, Giefer T, Wernert N, Pfeifer U. Stromal

nodules in benign prostatic hyperplasia. Eur Urol 1996;29:34554

18. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia

(BPH) an immune inflammatory disease? Eur Urol 2007;51: 120216.

19. Lepor H. Pathophysiology, Epidemiology, and Natural History of Benign

Prostatic Hyperplasia. Rev Urol. 2004;6(suppl 9):S3-S10

20. Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology

and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik
AB, Vaughan ED Jr, Wein AJ, eds. Campbells Urology, 8th ed.
Philadelphia, PA: WB Saunders Co; 2002:1297-1336

21. Tanguay S. Awde M, Brock G. Diagnosis and management of benign

prostatic hyperplasia in primary care. Can Urol Assoc J
2009;3(3Suppl2):S92-100

22. Edward JL. Diagnosis and Management of Benign Prostatic Hyperplasia.

AAFP. Volume 77, Number 10, 2008
23. American Urological Association. Guideline on the management of benign
prostatic hyperplasia (BPH). http://www.auanet.org/guidelines/bph.cfm.
diakses 2 September 2015

24. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-

specific antigen as a predictor of prostate volume in men with benign
prostatic hyperplasia. Urology. 1999;53(3):581-589

25. Logan YT, Belgeri MT. Monotherapy versus combination drug therapy for
the treatment of benign prostatic hyperplasia. Am J Geriatr Pharmacother.
2005;3(2):103-114.

26. Lepor H, Williford WO, Barry MJ, et al., for the Veterans Affairs
Cooperative Studies Benign Prostatic Hyperplasia Study Group. The
efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N
Engl J Med. 1996;335(8):533-539

27. Roehrborn CG, Boyle P, Bergner D, et al., for the PLESS Study Group.
Serum prostate-specific antigen and prostate volume predict long-term
changes in symptoms and flow rate: results of a four-year, randomized
trial comparing finasteride versus placebo. Urology. 1999;54(4):662-669.

28. Dull P, Reagan RW Jr, Bahnson RR. Managing benign prostatic

hyperplasia. Am Fam Physician. 2002; 66(1):77-84.

29. Wilson LC, Gilling PJ, Williams A, et al. A randomised trial comparing
holmium laser enucleation versus transurethral resection in the treatment
of prostates larger than 40 grams: results at 2 years. Eur Urol.
2006;50(3):569-573.

30. Shabbir M, Kirby R. Fact or fiction: what do the benign prostatic

hyperplasia data tell us? Curr Urol Rep. 2005;6(4):243-250